智飞生物前三季营收降66%亏损12亿元 去年净利降7成

Core Insights - The company Zhifei Biological (300122.SZ) reported a significant decline in financial performance for the first three quarters of 2025, with total revenue decreasing by 66.53% year-on-year to 7.63 billion yuan and a net loss attributable to shareholders of 1.21 billion yuan, a decrease of 156.86% compared to the previous year [1][2][3] Financial Performance Summary - Revenue: The company's revenue for the first three quarters of 2025 was 7.63 billion yuan, down 66.53% year-on-year [1][2] - Net Profit: The net profit attributable to shareholders was -1.21 billion yuan, reflecting a 156.86% decrease year-on-year [1][2] - Net Profit Excluding Non-Recurring Items: The net profit excluding non-recurring items was -1.23 billion yuan, a decline of 158.08% year-on-year [1][2] - Operating Cash Flow: The net cash flow from operating activities was 2.99 billion yuan, an increase of 201.18% year-on-year [1][2] 2024 Financial Overview - Revenue: In 2024, the company achieved a revenue of 26.07 billion yuan, a decrease of 50.74% compared to 2023 [3] - Net Profit: The net profit attributable to shareholders for 2024 was 2.02 billion yuan, down 74.99% year-on-year [3] - Net Profit Excluding Non-Recurring Items: The net profit excluding non-recurring items was 1.99 billion yuan, a decline of 74.84% compared to the previous year [3] - Operating Cash Flow: The net cash flow from operating activities was -4.41 billion yuan, a decrease of 149.06% year-on-year [3]